Published in Lab Business Week, February 25th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Addex Pharmaceuticals.
Report 1: Addex Pharmaceuticals announced the start of a phase IIa proof of concept study on lead compound ADX10059 in patients with moderately severe dental anxiety. This is the third indication in a phase IIa development program in which ADX10059 is also being evaluated for acute treatment of migraine and for prevention of acid reflux in patients with gastroesophageal reflux disease (GERD).
The latter two studies are being conducted in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.